FLT3 and acute myeloid leukemia: Also, off-target mutations include specific mutations such as TET2, RAS, and IDH1/2, activation of SYK and AXL (like Midostaurin and Quizartinib), upregulation of Pim and FLT3 ligand (FL) (such as Lestaurtinib, Midostaurin, Sorafenib, and Quizartinib), and preservation of FLT3-ITD AML cells in bone marrow microenvironment (like Quizartinib, Sorafenib, and Gilteritinib) [24–28].